Roche to divest from biologics manufacturing facility in Vacaville, California
Roche has announced their plans to divest from their legacy Genentech biologics manufacturing facility as part of a larger operations strategy after emailed letters were sent to facility employees informing them of the decision.
Swiss pharmaceutical company Roche has announced plans to sell a drug manufacturing facility in Vacaville, California, which boasts 800 employees. If a suitable buyer cannot be found, Roche has announced plans towards the closure of the plant in 2028/2029.
In a statement, the drugmaker stated plans to divest its legacy Genentech manufacturing facility as part of larger plans to develop broader strategies in the evolution of its manufacturing capabilities to meet therapeutic pipeline requirements. One of the oldest manufacturing sites under the Roche network, the facility specialises in large-scale production of biologics. The facility was purchased over 10 years ago with the purchase of US-based biotech Genentech by Roche. Drug products manufactured at the facility include cancer therapeutics Avastin and Herceptin. Actemra for the treatment of rheumatoid arthritis is also produced at the Vacaville plant. With the onset of the COVID-19 pandemic, Roche collaborated with Regeneron Pharmaceuticals to ramp up supply of Regeneron’s COVID-19 antibody treatment, which was achieved at the Vacaville plant.
In emails sent to employees of the Vacaville facility, the company stated that they did not expect the large volumes of biologics medicines produced by the site to be needed, with production to be shifted to a newer plant. Roche stated their intention to initiate a process of finding a buyer for the site, which is to be announced in due course. If a suitable investor cannot be found, plans will shift to ramping down operations towards a closure in 2028/2029.
Global Head of Pharma Technical Operations at Roche Susanne Hundsbaek-Pedersen stated: “The Vacaville site has a 25-year legacy of producing innovating medicines for millions of patients around the world. We aim to find a buyer who shares our values and respects the contributions and expertise of our colleagues at the facility.” Hundsbaek-Pedersen also assured that there would be no immediate effect to operations or employees: “At this time, there is no impact to operations, or to our employees, and we are committed to treating our colleagues in Vacaville with care and compassion throughout the process.”
Sources:
1. Roche to Divest Legacy Genentech Facility in Vacaville, California, as Part of Long-term Strategy to Evolve Manufacturing Capabilities [Accessed June 1, 2023] https://assets.cwp.roche.com/f/126832/x/41d2555bb3/20230531_roche_to_divest_genentech_facility.pdf
2. Exclusive: Roche looking to sell or shut down California biologic drug plant [Accessed June 1, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/roche-looking-sell-vacaville-california-plant-email-2023-05-31/
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance